NCT07211958Phase 3Recruiting

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

Study sponsor: Syndax Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-06Estimated
Enrollment · participants468Estimated
Source updated2026-10-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source